Matching articles for "Glucophage"
Issue 1742 · November 24, 2025
Noninsulin Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is…

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):185-92 doi:10.58347/tml.2025.1742a
Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.
Issue 1663 · November 14, 2022
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):177-84
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Issue 1599 · June 1, 2020 Free
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes

The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):88
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and extended-release metformin, for oral treatment of type 2 diabetes in adults. Empagliflozin and linagliptin have been available in a fixed-dose combination as Glyxambi since 2015, and both have been available in 2-drug combinations with extended-release metformin for years (see Table 1).
Issue 1584 · November 4, 2019
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can…

Med Lett Drugs Ther. 2019 Nov 4; 61(1584):169-78
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.
Issue 1583 · October 21, 2019
Oral Semaglutide (Rybelsus) for Type 2 Diabetes

An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults.…

Med Lett Drugs Ther. 2019 Oct 21; 61(1583):166-8
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Issue 1566 · February 25, 2019
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):26-8
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Issue 1527 · August 14, 2017
Cardiovascular Effects of Some Antidiabetic Drugs

For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):136-8
For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic retinopathy, nephropathy, neuropathy), but whether it prevents macrovascular complications (myocardial infarction [MI], stroke) has been less clear. The FDA now requires that cardiovascular safety studies be performed for all new drugs for type 2 diabetes.1 Recent findings that some of the newer second-line drugs for type 2 diabetes have cardiovascular benefits have led to new interest in the cardiovascular efficacy and safety of all antidiabetic drugs.
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1507 · November 7, 2016
Metformin for Prediabetes

The oral biguanide metformin ( Glucophage , and others) is generally the drug of choice for initial treatment of type 2 diabetes. It has also been used to prevent or at least delay the onset of diabetes in…

Med Lett Drugs Ther. 2016 Nov 7; 58(1507):141
The oral biguanide metformin ( Glucophage , and others) is generally the drug of choice for initial treatment of type 2 diabetes. It has also been used to prevent or at least delay the onset of diabetes in patients considered to be at high risk for the disease. Recent guidelines recommend considering use of metformin in patients with prediabetes (fasting plasma glucose 100-125 mg/dL, 2-hr post-load glucose 140-199 mg/dL, or A1C 5.7-6.4%), especially in those who are <60 years old, have a BMI >35 kg/m 2 , or have a history of gestational diabetes. Metformin has not been approved for such use by the FDA.
Issue 1500 · August 1, 2016
Jentadueto XR for Type 2 Diabetes

The FDA has approved Jentadueto XR (Boehringer Ingelheim/Lilly), a once-daily extended-release formulation of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the biguanide metformin, for oral…

Med Lett Drugs Ther. 2016 Aug 1; 58(1500):98-100
The FDA has approved Jentadueto XR (Boehringer Ingelheim/Lilly), a once-daily extended-release formulation of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the biguanide metformin, for oral treatment of type 2 diabetes. Linagliptin and metformin have been available for years in a twice-daily immediate-release combination (Jentadueto) . Once-daily extended-release formulations combining metformin with the DPP-4 inhibitors saxagliptin (Kombiglyze XR) and sitagliptin (Janumet XR) are also available.
Issue 1493 · April 25, 2016 Free
In Brief: New Recommendations for Use of Metformin in Renal Impairment

The FDA has required labeling changes that replace serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) as the parameter used to determine the appropriateness of treatment with the biguanide…

Med Lett Drugs Ther. 2016 Apr 25; 58(1493):51
The FDA has required labeling changes that replace serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) as the parameter used to determine the appropriateness of treatment with the biguanide metformin ( Glucophage , and others) in patients with renal impairment. These changes will allow more patients with mild to moderate renal impairment to receive metformin, which is generally the first drug prescribed for treatment of type 2 diabetes. Metformin was previously contraindicated in women with a SCr level ≥1.4 mg/dL and in men with a SCr level ≥1.5 mg/dL, but use of SCr as a surrogate indicator tends to underestimate renal function in certain populations (e.g., younger patients, men, black patients, patients with greater muscle mass). The calculation of eGFR takes into account age, race, and sex, as well as SCr level, providing a more accurate assessment of kidney function. A literature review summarized in an FDA Drug Safety Communication concluded that, based on eGFR, metformin is safe to use in patients with mild renal impairment and in some patients with moderate renal impairment. 1 The eGFR should be calculated before patients begin treatment with metformin and at least annually thereafter. Metformin is now contraindicated in patients with an eGFR <30 mL/min/1.73 m 2 , and starting treatment with the drug in patients with an eGFR between 30 and 45 mL/min/1.73 m 2 is not recommended. If the eGFR falls below 45 mL/min/1.73 m 2 in a patient already taking metformin, the benefits and risks of continuing treatment should be assessed. Metformin should be not be administered for 48 hours after an iodinated contrast imaging procedure in patients with an eGFR <60 mL/min/1.73 m 2 or a history of liver disease, alcoholism, or heart failure, or in those receiving intra-arterial contrast, and the eGFR should be re-evaluated before treatment is restarted. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: www.fda.gov. Accessed April 14, 2016. Download complete U.S. English article
Issue 1484 · December 21, 2015
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes

The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage , and others),…

Med Lett Drugs Ther. 2015 Dec 21; 57(1484):172-4
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage , and others), for treatment of patients with type 2 diabetes not adequately controlled on either of these drugs alone or already being treated with both empagliflozin and metformin. It is the third SGLT2 inhibitor/metformin combination to be approved in the US.
Issue 1462 · February 16, 2015
Diet, Drugs, and Surgery for Weight Loss

Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity can…

Med Lett Drugs Ther. 2015 Feb 16; 57(1462):21-8
Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight, but long-term failure rates are high. Several drugs have been approved by the FDA for weight reduction, but adherence is poor, adverse effects are common, and patients usually regain the lost weight when the drug is stopped. Bariatric surgery can produce substantial weight loss and significantly reduce obesity-related comorbidities; long-term data on its safety are encouraging, but still limited. Guidelines for the management of overweight or obese adults have recently been published.
Issue 1416 · May 13, 2013
Canagliflozin (Invokana) for Type 2 Diabetes

Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.

Med Lett Drugs Ther. 2013 May 13; 55(1416):37-9
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.
Issue 1395 · July 23, 2012
What Comes After Metformin for Type 2 Diabetes?

Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):58-9
Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. A recent article in The Medical Letter offered some support for a sulfonylurea. Three recent trials published in The Lancet favored the long-acting basal insulin glargine, the glucagon-like peptide (GLP-1) analog exenatide, and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, respectively. Some of the advantages and disadvantages of these and other available agents are listed in Table 1 on the opposite page.
Issue 1390 · May 14, 2012
Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes

Linagliptin (Tradjenta) and metformin ( Glucophage , and others) are now available as a fixed-dose combination ( Jentadueto – Boehringer Ingelheim/Lilly) for oral treatment of type 2 diabetes in adults.…

Med Lett Drugs Ther. 2012 May 14; 54(1390):37-9
Linagliptin (Tradjenta) and metformin ( Glucophage , and others) are now available as a fixed-dose combination ( Jentadueto – Boehringer Ingelheim/Lilly) for oral treatment of type 2 diabetes in adults. Metformin is generally the preferred first-line agent for treatment of type 2 diabetes, but most patients eventually require treatment with multiple drugs. Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor like sitagliptin (Januvia) and saxagliptin (Onglyza) . Both sitagliptin and saxagliptin are also available in fixed-dose combinations with metformin.
Issue 1377 · November 14, 2011
Sitagliptin and Simvastatin (Juvisync)

The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin ( Zocor , and others).

Med Lett Drugs Ther. 2011 Nov 14; 53(1377):89
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin ( Zocor , and others).
Issue 1376 · October 31, 2011
Drugs for Ovulation Induction

Infertility occurs in about 15% of couples. About one-third of cases are due to problems with ovulation or other female factors, another third are due to a male infertility factor, and the remaining third are…

Med Lett Drugs Ther. 2011 Oct 31; 53(1376):86-8
Infertility occurs in about 15% of couples. About one-third of cases are due to problems with ovulation or other female factors, another third are due to a male infertility factor, and the remaining third are unexplained. In older women, unexplained infertility is probably caused by diminished quality and quantity of oocytes. The first approach to treatment of female-factor infertility generally is the use of drugs that stimulate oocyte production.
Issue 108 · August 1, 2011
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production.…

Treat Guidel Med Lett. 2011 Aug; 9(108):47-54
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 104 · April 1, 2011
Diet, Drugs and Surgery for Weight Loss

Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.

Treat Guidel Med Lett. 2011 Apr; 9(104):17-22
Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.
Issue 1335 · April 5, 2010
Liraglutide (Victoza) for Type 2 Diabetes

Liraglutide ( Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can…

Med Lett Drugs Ther. 2010 Apr 5; 52(1335):25-7
Liraglutide ( Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin ( Glucophage , and others) or glimepiride ( Amaryl , and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Issue 1333 · March 8, 2010
Rosiglitazone (Avandia) Revisited

The cardiovascular safety of the thiazolidinedione rosiglitazone ( Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19,…

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):17
The cardiovascular safety of the thiazolidinedione rosiglitazone ( Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Issue 1324 · November 2, 2009
Saxagliptin (Onglyza) for Type 2 Diabetes

Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):85-6
Saxagliptin ( Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Issue 1313 · June 1, 2009
Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes

A new fixed-dose tablet ( PrandiMet - Novo Nordisk) combining metformin ( Glucophage , and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already…

Med Lett Drugs Ther. 2009 Jun 1; 51(1313):41-3
A new fixed-dose tablet ( PrandiMet - Novo Nordisk) combining metformin ( Glucophage , and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for patients not adequately controlled on either drug alone.
Issue 71 · July 1, 2008
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,…

Treat Guidel Med Lett. 2008 Jul; 6(71):47-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 1285 · May 5, 2008 Free
In Brief: A New Indication for Colesevelam (Welchol)

Colesevelam ( Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102 ), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the…

Med Lett Drugs Ther. 2008 May 5; 50(1285):33
Colesevelam ( Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102 ), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the treatment of type 2 diabetes. In unpublished studies summarized in the package insert, patients with type 2 diabetes taking metformin ( Glucophage , and others), a sulfonylurea or insulin (each as either monotherapy or in combination with other anti-diabetic agents) were given colesevelam 3800 mg per day or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c) by about 0.5% more than placebo in all three trials. The mechanism is unclear. Colesevelam can cause constipation, nausea and dyspepsia, increase serum triglyceride concentrations, and interfere with absorption of other oral drugs. One month's treatment with Welchol obtained from drugstore.com would cost about $200. Medical Letter consultants are not enthusiastic about prescribing it for this indication. Download U.S. English
Issue 68 · April 1, 2008
Diet, Drugs and Surgery for Weight Loss

Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing…

Treat Guidel Med Lett. 2008 Apr; 6(68):23-7
Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight but are associated with high long-term failure rates. Drugs may help some patients, but all currently available drugs for weight reduction have drawbacks. Gastric surgery can produce marked weight loss in the severely obese, but long-term data on safety are limited.
Issue 1262 · June 4, 2007
Sitagliptin/Metformin (Janumet) for Type 2 Diabetes

Sitagliptin (Januvia) and metformin ( Glucophage , and others) are now available in a single tablet ( Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in…

Med Lett Drugs Ther. 2007 Jun 4; 49(1262):45-7
Sitagliptin (Januvia) and metformin ( Glucophage , and others) are now available in a single tablet ( Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in patients not adequately controlled by sitagliptin or meformin alone or in those already taking both drugs. Metformin is also available in combination with the thiazolidinediones pioglitazone and rosiglitazone and with the sulfonylureas glipizide and glyburide.
Issue 1227 · January 30, 2006
Pioglitazone/Metformin (Actoplus met)

For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination ( Actoplus met - Takeda) of two widely used…

Med Lett Drugs Ther. 2006 Jan 30; 48(1227):9-11
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination ( Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin ( Glucophage , and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone. Rosiglitazone, another thiazolidinedione, is also available in a fixed-dose combination with metformin (Avandamet) .
Issue 36 · August 1, 2005
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In…

Treat Guidel Med Lett. 2005 Aug; 3(36):57-62
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In many patients, diet and regular exercise can improve glucose control. Most drugs currently available for management of type 2 diabetes increase insulin supply (sulfonylureas, other secretagogues and insulin itself), decrease insulin resistance (thiazolidinediones) or improve the effectiveness of insulin (biguanides). Alpha-glucosidase inhibitors reduce the rate of glucose absorption. Newer agents such as pramlintide (Symlin) and exenatide (Byetta) have multiple effects to increase satiety and reduce postprandial hyperglycemia.
Issue 1210 · June 6, 2005
Exenatide (Byetta) for Type 2 Diabetes

Exenatide injection ( Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2…

Med Lett Drugs Ther. 2005 Jun 6; 47(1210):45-6
Exenatide injection ( Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin ( Glucophage , and others), a sulfonylurea, such as glyburide ( DiaBeta , and others), or both. Exenatide is not indicated for use with insulin.
Issue 1188 · August 2, 2004
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available…

Med Lett Drugs Ther. 2004 Aug 2; 46(1188):63-4
Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Issue 16 · December 1, 2003
Diet, Drugs and Surgery for Weight Loss

The latest definitions of overweight and obesity are based on body mass index (BMI). The BMI is calculated by dividing the weight in kilograms by the square of the height in meters (kg/m 2 ). More than half of…

Treat Guidel Med Lett. 2003 Dec; 1(16):101-6
The latest definitions of overweight and obesity are based on body mass index (BMI). The BMI is calculated by dividing the weight in kilograms by the square of the height in meters (kg/m 2 ). More than half of American adults are considered overweight with a BMI of ≥25, and about one third are obese with a BMI of ≥30. All ages seem to be affected; the proportion of children and adolescents who are overweight has more than doubled in the past 25 years. There is no lack of effort to treat obesity: drugs, diets and programs to change lifestyle are the basis for a large and flourishing industry. The frequent failure of diet and drug treatment sometimes leads to recommendations for surgery, usually restricted to those with a BMI ≥40.
Issue 14 · October 1, 2003
Drugs for Assisted Reproduction

Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or…

Treat Guidel Med Lett. 2003 Oct; 1(14):89-92
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Issue 1155 · April 28, 2003
Insulin-Sensitizing Drugs for Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and…

Med Lett Drugs Ther. 2003 Apr 28; 45(1155):35-6
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin resistance. In recent years, antidiabetic drugs, although not approved for such use by the FDA, have been tried for treatment of this disorder. This review describes the effectiveness of metformin and the thiazolidinediones in women with PCOS. Also included is a dosage and cost table for some insulin-sensitizing drugs.
Issue 1146 · December 23, 2002
Metaglip and Avandamet for Type 2 Diabetes

Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line…

Med Lett Drugs Ther. 2002 Dec 23; 44(1146):107-9
Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line treatment when control is not adequate on metformin or a sulfonylurea alone. Avandamet (GlaxoSmithKline), a combination of metformin and rosiglitazone, is approved by the FDA only as second-line therapy for patients who are not well controlled on metformin alone, or are already taking both metformin and rosiglitazone. Glucovance (Bristol-Myers Squibb), a combination of metformin and glyburide, a sulfonylurea similar to glipizide, has been available since 2000 ( Medical Letter 2000; 42:105 ).
Issue 1 · September 1, 2002
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most…

Treat Guidel Med Lett. 2002 Sep; 0(1):1-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most drugs currently available for management of type 2 diabetes fall into 2 categories: those that increase insulin supply (sulfonylureas, other secretagogues and insulin itself) and those that decrease insulin resistance or improve its effectiveness (biguanides, thiazolidinediones). Alpha-glucosidase inhibitors reduce the rate of glucose absorption.
Issue 1101 · April 2, 2001
Nateglinide For Type 2 Diabetes

Nateglinide (Starlix) , a new meglitinide oral glucose-lowering agent, has been approved by the FDA.

Med Lett Drugs Ther. 2001 Apr 2; 43(1101):29-30
Nateglinide (Starlix) , a new meglitinide oral glucose-lowering agent, has been approved by the FDA.
Issue 1092 · November 13, 2000
Glyburide/Metformin (Glucovance) for Type 2 Diabetes

A fixed-dose combination of two antihyperglycemic drugs, glyburide and metformin, has been approved by the US FDA for initial treatment of type 2 diabetes or when glucose control is unsatisfactory with either…

Med Lett Drugs Ther. 2000 Nov 13; 42(1092):105-6
A fixed-dose combination of two antihyperglycemic drugs, glyburide and metformin, has been approved by the US FDA for initial treatment of type 2 diabetes or when glucose control is unsatisfactory with either drug alone
Issue 1075 · April 3, 2000
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma

Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.

Med Lett Drugs Ther. 2000 Apr 3; 42(1075):31-2
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.
Issue 1066 · November 19, 1999
Pioglitazone (Actos)

Pioglitazone is the third thiazolidinedione ("glitazone") to be marketed in the USA for treatment of type 2 diabetes. Thiazolidinediones decrease resistance to insulin.

Med Lett Drugs Ther. 1999 Nov 19; 41(1066):112
Pioglitazone is the third thiazolidinedione ("glitazone") to be marketed in the USA for treatment of type 2 diabetes. Thiazolidinediones decrease resistance to insulin.
Issue 1059 · August 13, 1999
Rosiglitazone for Type 2 Diabetes Mellitus

Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.

Med Lett Drugs Ther. 1999 Aug 13; 41(1059):71-3
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.
Issue 1053 · May 21, 1999
Miglitol for Type 2 Diabetes Mellitus

Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.

Med Lett Drugs Ther. 1999 May 21; 41(1053):49-50
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
Issue 1027 · May 22, 1998
Repaglinide for Type 2 Diabetes Mellitus

Repaglinide ( Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for…

Med Lett Drugs Ther. 1998 May 22; 40(1027):55-6
Repaglinide ( Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for monotherapy or for use in combination with metformin.
Issue 1003 · June 20, 1997
Midodrine for Orthostatic Hypotension

Midodrine hydrochloride ( ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition…

Med Lett Drugs Ther. 1997 Jun 20; 39(1003):59-60
Midodrine hydrochloride ( ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition include other sympathomimetics, constrictive garments, erythropoietin ( Epogen ; Procrit) and fludrocortisone with salt (D Robertson and TL Davis, Neurology, 45 suppl 5: S26, 1995).
Issue 1001 · May 23, 1997
Troglitazone for Non-Insulin-Dependent Diabetes Mellitus

Troglitazone ( Rezulin - Parke-Davis), the first of a new class of thiazolidinedione derivatives ('glitazones') for diabetes, has been marketed for oral treatment of noninsulin- dependent diabetes mellitus…

Med Lett Drugs Ther. 1997 May 23; 39(1001):49-51
Troglitazone ( Rezulin - Parke-Davis), the first of a new class of thiazolidinedione derivatives ('glitazones') for diabetes, has been marketed for oral treatment of noninsulin- dependent diabetes mellitus (NIDDM) in patients who take more than 30 units of insulin daily and still have a glycosylated hemoglobin concentration (HbA1c) of 8.5% or higher.
Issue 975 · May 24, 1996
Glimepiride for NIDDM

Glimepiride (Amaryl - Hoechst Marion Roussel), a new sulfonylurea similar to glyburide and glipizide (Medical Letter, 26:79, 1984), was recently marketed for treatment of patients with non-insulin-dependent…

Med Lett Drugs Ther. 1996 May 24; 38(975):47-8
Glimepiride (Amaryl - Hoechst Marion Roussel), a new sulfonylurea similar to glyburide and glipizide (Medical Letter, 26:79, 1984), was recently marketed for treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not controlled by diet and exercise. The new drug is the first sulfonylurea approved by the US Food and Drug Administration (FDA) for use concurrently with insulin.
Issue 967 · February 2, 1996
Acarbose for Diabetes Mellitus

Acarbose (Precose -Bayer), an oral alpha-glucosidase inhibitor that has been available in Europe for several years, was recently approved by the US Food and Drug Administration (FDA) for treatment of…

Med Lett Drugs Ther. 1996 Feb 2; 38(967):9-10
Acarbose (Precose -Bayer), an oral alpha-glucosidase inhibitor that has been available in Europe for several years, was recently approved by the US Food and Drug Administration (FDA) for treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Issue 948 · May 12, 1995
Metformin for Non-Insulin-Dependent Diabetes Mellitus

Metformin ( Glucophage - Bristol-Myers Squibb), a hypoglycemic agent, was recently marketed in the USA for oral treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not adequately…

Med Lett Drugs Ther. 1995 May 12; 37(948):41-2
Metformin ( Glucophage - Bristol-Myers Squibb), a hypoglycemic agent, was recently marketed in the USA for oral treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not adequately controlled by diet alone. Previously marketed in more than ninety countries, including Canada, metformin (dimethylbiguanide) is chemically related to phenformin (phenylethylbiguanide), which was withdrawn from the US market in 1976 because it caused a high incidence of lactic acidosis. In approving metformin, the US Food and Drug Administration stipulated that a post-marketing controlled trial of 10,000 patients be conducted to determine the incidence of lactic acidosis.